An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models
27 August 2023 (10:25 - 10:35)
Organised by: 

About the speaker

Verve Therapeutics, Boston (United States of America)
5 More presentations in this session

Doctor P. Burger (Utrecht, NL)

Associate Professor T. Osadnik (Zabrze, PL)
Access the full session
The Event
ESC Congress 2023
27 August 2023
10:25 CET
You may be interested in
Congress Presentation
Congress Session




